Studies examining chronic Trem2 activation in AD mouse models, have shown lowered Aβ pathology after anti-Trem2 antibody treatment [104–107], while effects on Tau pathology remain conflicting [105, 106]. The gene discussed is MAPT; the disease is Alzheimer disease.